{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:52:03Z","timestamp":1793656323393,"version":"4.5.1"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T00:00:00Z","timestamp":1657843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ajog.2022.07.023","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T21:52:49Z","timestamp":1658181169000},"page":"880.e1-880.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections"],"prefix":"10.1016","volume":"227","author":[{"given":"Mark G.","family":"Martens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem","family":"Maximos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9424-0931","authenticated-orcid":false,"given":"Thorsten","family":"Degenhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3622-6357","authenticated-orcid":false,"given":"Stacey","family":"Curelop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ghannoum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Flynt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1796-5584","authenticated-orcid":false,"given":"Stephen R.","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2022.07.023_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ajog.2015.06.067","article-title":"Recurrent vulvovaginal candidiasis","volume":"214","author":"Sobel","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.07.023_bib2","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1016\/S1473-3099(18)30103-8","article-title":"Global burden of recurrent vulvovaginal candidiasis: a systematic review","volume":"18","author":"Denning","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ajog.2022.07.023_bib3","first-page":"238","article-title":"Prevalence of non-albicans Candida infections in women with recurrent vulvovaginal symptomatology","volume":"3","author":"Mintz","year":"2013","journal-title":"Adv Infect Dis"},{"key":"10.1016\/j.ajog.2022.07.023_bib4","first-page":"121","article-title":"An update on the roles of non-albicans Candida species in vulvovaginitis","volume":"4","author":"Makanjuola","year":"2018","journal-title":"J\u00a0Fungi (Basel)"},{"key":"10.1016\/j.ajog.2022.07.023_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1080\/14656566.2018.1476490","article-title":"Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species","volume":"19","author":"Sobel","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ajog.2022.07.023_bib6","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/AOG.0b013e31827307b2","article-title":"Fluconazole-resistant Candida albicans vulvovaginitis","volume":"120","author":"Marchaim","year":"2012","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.07.023_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","article-title":"Sexually transmitted infections treatment guidelines, 2021","volume":"70","author":"Workowski","year":"2021","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.ajog.2022.07.023_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.annepidem.2017.08.010","article-title":"Recurrent vulvovaginal candidiasis","volume":"27","author":"Blostein","year":"2017","journal-title":"Ann Epidemiol"},{"key":"10.1016\/j.ajog.2022.07.023_bib9","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/j.1471-0528.2008.01830.x","article-title":"Mannose-binding lectin gene polymorphism and resistance to therapy in women with recurrent vulvovaginal candidiasis","volume":"115","author":"Donders","year":"2008","journal-title":"BJOG"},{"key":"10.1016\/j.ajog.2022.07.023_bib10","doi-asserted-by":"crossref","first-page":"e12811","DOI":"10.1111\/aji.12811","article-title":"Is non-response to fluconazole maintenance therapy for recurrent Candida vaginitis related to sensitization to atopic reactions?","volume":"79","author":"Donders","year":"2018","journal-title":"Am J Reprod Immunol"},{"key":"10.1016\/j.ajog.2022.07.023_bib11","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ajog.2022.07.023_bib12","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1128\/AAC.03707-14","article-title":"The clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzyme","volume":"58","author":"Warrilow","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ajog.2022.07.023_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1056\/NEJMoa033114","article-title":"Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis","volume":"351","author":"Sobel","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.07.023_bib15","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/LGT.0000000000000496","article-title":"Prognosis and long-term outcome of women with idiopathic recurrent vulvovaginal candidiasis caused by Candida albicans","volume":"24","author":"Collins","year":"2020","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2022.07.023_bib16","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1128\/JCM.03044-13","article-title":"Impact of new antifungal breakpoints on antifungal resistance in Candida species","volume":"52","author":"Fothergill","year":"2014","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.ajog.2022.07.023_bib17","unstructured":"Data on file. Mycovia Pharmaceuticals, Inc. 2021."},{"key":"10.1016\/j.ajog.2022.07.023_bib18","doi-asserted-by":"crossref","first-page":"624.e1","DOI":"10.1016\/j.ajog.2018.03.001","article-title":"A\u00a0phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161\u00a0in\u00a0the treatment of recurrent vulvovaginal candidiasis","volume":"218","author":"Brand","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.07.023_bib19","unstructured":"Study of oral oteseconazole (VT-1161) for\u00a0acute yeast infections in patients with recurrent yeast infections (ultraVIOLET). Clinicaltrials.gov identifier: NCT0340616. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03840616. Accessed August 10, 2022."},{"key":"10.1016\/j.ajog.2022.07.023_bib20","article-title":"FDA approves Mycovia Pharmaceuticals\u2019 VIVJOA\u2122 (oteseconazole), the first and only FDA-approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection)","year":"2022","journal-title":"News release"},{"key":"10.1016\/j.ajog.2022.07.023_bib21","article-title":"Vivjoa. Prescribing information","year":"2022","journal-title":"Mycovia Inc"},{"key":"10.1016\/j.ajog.2022.07.023_bib22","article-title":"A study of oral oteseconazole for the treatment of patients with recurrent vaginal candidiasis (yeast infection) (VIOLET)","year":"2022","journal-title":"Clinicaltrials.gov\u00a0identifier: NCT03562156"},{"key":"10.1016\/j.ajog.2022.07.023_bib23","article-title":"A study of oral oteseconazole (VT-1161) for the treatment of patients with recurrent vaginal candidiasis (yeast infection) (VIOLET). Clinicaltrials","year":"2021","journal-title":"gov identifier: NCT03561701"},{"key":"10.1016\/j.ajog.2022.07.023_bib24","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100055","article-title":"Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis","volume":"1","author":"Sobel","year":"2022","journal-title":"NEJM Evid"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822005774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822005774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:39:11Z","timestamp":1757590751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937822005774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0002937822005774"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2022.07.023","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 3 study evaluating the safety and efficacy of oteseconazole in the treatment of recurrent vulvovaginal candidiasis and acute vulvovaginal candidiasis infections","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2022.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}